vs
Idexx Laboratories（IDXX）とPrimerica, Inc.（PRI）の財務データ比較。上の社名をクリックして会社を切り替えられます
Idexx Laboratoriesの直近四半期売上が大きい（$1.1B vs $853.7M、Primerica, Inc.の約1.3倍）。Primerica, Inc.の純利益率が高く（23.1% vs 22.8%、差は0.3%）。Idexx Laboratoriesの前年同期比売上増加率が高い（14.3% vs 11.0%）。過去8四半期でPrimerica, Inc.の売上複合成長率が高い（7.2% vs 6.4%）
IDEXXラボラトリーズは1983年設立の米国多国籍企業で、伴侶動物獣医療、家畜・家禽、水質検査、乳製品分野向けの製品・サービスの開発・製造・流通を手がけています。本社はメイン州ウェストブルックにあり、EMEA地域の拠点はオランダのホーフドルプに置かれています。
Primerica, Inc.はマルチレベルマーケティングを事業モデルとする金融サービス企業で、米国とカナダの中所得層の家族を主な対象に、保険や投資をはじめとする各種金融商品・サービスを提供している。
IDXX vs PRI — 直接比較
売上が大きい
IDXX
1.3倍大きい
$853.7M
売上成長率が高い
IDXX
+3.2%の差
11.0%
純利益率が高い
PRI
純利益率が0.3%高い
22.8%
2年売上CAGRが高い
PRI
2年複合成長率
6.4%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.1B | $853.7M |
| 純利益 | $248.2M | $197.0M |
| 粗利率 | 60.3% | — |
| 営業利益率 | 28.9% | 28.9% |
| 純利益率 | 22.8% | 23.1% |
| 売上前年比 | 14.3% | 11.0% |
| 純利益前年比 | 14.8% | 17.9% |
| EPS（希薄化後） | $3.09 | $6.11 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上IDXXPRI
| Q4 25 | $1.1B | $853.7M | ||
| Q3 25 | $1.1B | $839.9M | ||
| Q2 25 | $1.1B | $793.3M | ||
| Q1 25 | $998.4M | $804.8M | ||
| Q4 24 | $954.3M | $768.8M | ||
| Q3 24 | $975.5M | $774.1M | ||
| Q2 24 | $1.0B | $803.4M | ||
| Q1 24 | $964.1M | $742.8M |
純利益IDXXPRI
| Q4 25 | $248.2M | $197.0M | ||
| Q3 25 | $274.6M | $206.8M | ||
| Q2 25 | $294.0M | $178.3M | ||
| Q1 25 | $242.7M | $169.1M | ||
| Q4 24 | $216.1M | $167.1M | ||
| Q3 24 | $232.8M | $164.4M | ||
| Q2 24 | $203.3M | $1.2M | ||
| Q1 24 | $235.6M | $137.9M |
粗利率IDXXPRI
| Q4 25 | 60.3% | — | ||
| Q3 25 | 61.8% | — | ||
| Q2 25 | 62.6% | — | ||
| Q1 25 | 62.4% | — | ||
| Q4 24 | 59.8% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.7% | 98.0% | ||
| Q1 24 | 61.5% | 98.2% |
営業利益率IDXXPRI
| Q4 25 | 28.9% | 28.9% | ||
| Q3 25 | 32.1% | 32.3% | ||
| Q2 25 | 33.6% | 29.6% | ||
| Q1 25 | 31.7% | 27.5% | ||
| Q4 24 | 27.4% | 64.7% | ||
| Q3 24 | 31.2% | 32.9% | ||
| Q2 24 | 26.3% | 1.0% | ||
| Q1 24 | 31.0% | 24.1% |
純利益率IDXXPRI
| Q4 25 | 22.8% | 23.1% | ||
| Q3 25 | 24.8% | 24.6% | ||
| Q2 25 | 26.5% | 22.5% | ||
| Q1 25 | 24.3% | 21.0% | ||
| Q4 24 | 22.7% | 21.7% | ||
| Q3 24 | 23.9% | 21.2% | ||
| Q2 24 | 20.3% | 0.1% | ||
| Q1 24 | 24.4% | 18.6% |
EPS（希薄化後）IDXXPRI
| Q4 25 | $3.09 | $6.11 | ||
| Q3 25 | $3.40 | $6.35 | ||
| Q2 25 | $3.63 | $5.40 | ||
| Q1 25 | $2.96 | $5.05 | ||
| Q4 24 | $2.62 | $4.92 | ||
| Q3 24 | $2.80 | $4.83 | ||
| Q2 24 | $2.44 | $0.03 | ||
| Q1 24 | $2.81 | $3.93 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.1M | $756.2M |
| 総負債低いほど良い | $450.0M | — |
| 株主資本純資産 | $1.6B | $2.4B |
| 総資産 | $3.4B | $15.0B |
| 負債/資本比率低いほどレバレッジが低い | 0.28× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資IDXXPRI
| Q4 25 | $180.1M | $756.2M | ||
| Q3 25 | $208.2M | $644.9M | ||
| Q2 25 | $164.6M | $621.2M | ||
| Q1 25 | $164.0M | $625.1M | ||
| Q4 24 | $288.3M | $687.8M | ||
| Q3 24 | $308.6M | $550.1M | ||
| Q2 24 | $401.6M | $627.3M | ||
| Q1 24 | $397.4M | $593.4M |
総負債IDXXPRI
| Q4 25 | $450.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $617.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
株主資本IDXXPRI
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.6B | $2.3B | ||
| Q2 25 | $1.5B | $2.3B | ||
| Q1 25 | $1.4B | $2.3B | ||
| Q4 24 | $1.6B | $2.3B | ||
| Q3 24 | $1.6B | $1.9B | ||
| Q2 24 | $1.6B | $2.1B | ||
| Q1 24 | $1.6B | $2.2B |
総資産IDXXPRI
| Q4 25 | $3.4B | $15.0B | ||
| Q3 25 | $3.4B | $14.8B | ||
| Q2 25 | $3.3B | $14.8B | ||
| Q1 25 | $3.2B | $14.6B | ||
| Q4 24 | $3.3B | $14.6B | ||
| Q3 24 | $3.4B | $14.8B | ||
| Q2 24 | $3.4B | $14.6B | ||
| Q1 24 | $3.4B | $14.9B |
負債/資本比率IDXXPRI
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $355.8M | $338.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $326.3M | — |
| FCFマージンFCF / 売上 | 29.9% | — |
| 設備投資強度設備投資 / 売上 | 2.7% | — |
| キャッシュ転換率営業CF / 純利益 | 1.43× | 1.72× |
| 直近12ヶ月FCF直近4四半期 | $1.1B | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローIDXXPRI
| Q4 25 | $355.8M | $338.2M | ||
| Q3 25 | $402.3M | $202.9M | ||
| Q2 25 | $185.7M | $162.6M | ||
| Q1 25 | $238.0M | $197.5M | ||
| Q4 24 | $262.0M | $270.6M | ||
| Q3 24 | $220.1M | $207.3M | ||
| Q2 24 | $248.3M | $173.3M | ||
| Q1 24 | $198.6M | $210.9M |
フリーキャッシュフローIDXXPRI
| Q4 25 | $326.3M | — | ||
| Q3 25 | $371.2M | — | ||
| Q2 25 | $151.6M | — | ||
| Q1 25 | $207.9M | — | ||
| Q4 24 | $232.8M | — | ||
| Q3 24 | $192.0M | — | ||
| Q2 24 | $215.0M | — | ||
| Q1 24 | $168.3M | — |
FCFマージンIDXXPRI
| Q4 25 | 29.9% | — | ||
| Q3 25 | 33.6% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 20.8% | — | ||
| Q4 24 | 24.4% | — | ||
| Q3 24 | 19.7% | — | ||
| Q2 24 | 21.4% | — | ||
| Q1 24 | 17.5% | — |
設備投資強度IDXXPRI
| Q4 25 | 2.7% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 2.9% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 3.1% | — |
キャッシュ転換率IDXXPRI
| Q4 25 | 1.43× | 1.72× | ||
| Q3 25 | 1.47× | 0.98× | ||
| Q2 25 | 0.63× | 0.91× | ||
| Q1 25 | 0.98× | 1.17× | ||
| Q4 24 | 1.21× | 1.62× | ||
| Q3 24 | 0.95× | 1.26× | ||
| Q2 24 | 1.22× | 147.98× | ||
| Q1 24 | 0.84× | 1.53× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
PRI
| Revenues From Sources Other Than Contracts With Customers | $445.9M | 52% |
| Investment And Savings Products Segment Revenues | $340.3M | 40% |
| Other | $56.5M | 7% |
| Segment Revenues From Contracts With Customers | $11.0M | 1% |
